ABcann Appoints New Chief Marketing Officer
NAPANEE, Ontario, Jan. 05, 2018 (GLOBE NEWSWIRE) — ABCANN GLOBAL CORPORATION (TSX-V:ABCN) (“ABcann” or the “Company”) is pleased to announce the appointment of Sung Kang as the Company’s Chief Marketing Officer (CMO). Mr. Kang, who will assume the position effective January 8, 2018, was formerly the Head of Marketing for the Mike’s Beverage Company, Canada’s leading ready-to-drink and cider business, owned by Labatt Breweries of Canada.
With more than 17 years of marketing experience, Mr. Kang has also held senior marketing leadership roles at companies including General Mills, Novartis Consumer Health, and Mark Anthony Group. His diverse background in consumer packaged goods (CPG)/food, pharma and alcohol has given him extensive experience managing large brand portfolios as well as uncovering powerful consumer insights that lead to category expanding new product innovations within regulated industries.
Sung is a great addition to the leadership team. We believe his marketing expertise combined with his experience in the alcohol and consumer health industries will prove invaluable to ABcann’s future growth. He knows how to leverage marketing analytics to create unique brands and effective promotions, and has a proven record of pushing the boundaries of consumer brands using disruptive innovation.
Barry Fishman, Chief Executive Officer of ABcann
As ABcann’s CMO, Mr. Kang will lead the Company’s branding, product innovation, customer marketing, consumer insights and advertising, as well as market access, key account management and digital initiatives. He will be responsible for developing and executing strategies aimed at positioning ABcann as a leading medical and adult-use cannabis company and driving profitable revenue.
In connection with Mr. Kang’s appointment, the Company has agreed to grant Mr. Kang 300,000 stock options, each of which will be exercisable into one common share in the capital of the Company until January 5, 2023 at a price of $1.77 per share, being the closing price per share on the TSX Venture Exchange on January 4, 2018. The options will vest quarterly over 36 months.
ABcann holds production and sales licenses from Health Canada. Its flagship facility in Napanee, Ontario contains proprietary plant-growing technology, centred on its specially designed, environmentally-controlled growing chambers. This approach results in the production of pharmaceutical-grade cannabis products.
The Company is expanding its cultivation capacity and pursuing partnership and product development opportunities domestically, as well as in select international markets, such as Germany, Australia and Israel.